hinese innovative biopharma companies are making remarkable strides in global expansion; to evolve from product globalization to true global competitiveness and brand recognition, these companies must prioritize strategic global talent acquisition and precise role placement. This will necessitate the progressive building of an international organizational framework with sustainable operational capacity, ensuring long-term success in the global biopharma arena. However, they face critical challenges in international talent management that pose risks to their overseas growth.

To help address these challenges, the Blue Book Opportunities and Challenges for International Talent in China’s Innovative Pharma Companies’ Global Expansion (Chinese only) was officially released at the Talent Forum at the DIA China Annual Meeting in Shanghai in 2025.

Based on extensive research by DIA’s Talent Development and Global Exchange Committee—including surveys and in-depth interviews with executives from more than 20 pharmaceutical companies—to gather industry insights, the Blue Book consolidates key challenges, shared experiences, and strategic recommendations, to provide a framework to explore best practices in international talent development and core competency enhancement.

Surveys and interviews reveal that Chinese innovative biopharma companies currently expanding overseas tend to maintain lean international team structures, reflecting the early-stage nature of their global strategic experimentation.

Most companies operate with overseas teams of fewer than 100 employees, with 20-50 employees being the most common range—representing roughly 40% of survey responses.

According to survey results on the functions covered by overseas employers, approximately 80% of interviewees indicated involvement in “research and development” (R&D) and 73% in “clinical,” but only 40% in “sales” (half the proportion seen in R&D and clinical functions). In contrast to R&D, commercial capabilities remain underdeveloped, with most companies yet to establish fully localized, end-to-end commercial operations.

These structural characteristics reflect the nascent phase of global expansion, which faces several specific challenges.

The most acute is the talent supply crisis, marked by severe shortages of professionals with the essential competencies: (1) cross-cultural fluency; (2) international regulatory expertise; and (3) global business acumen. Compounding this is the alarmingly high turnover among overseas leaders fueled by ambiguous strategic direction, weak cultural integration, and inefficient cross-border collaboration. According to one industry executive search expert, less than 10% of C-level executives at pharmaceutical companies expanding overseas remain with that company for more than three years, even though executives typically need about three years to develop strategies, including building teams and validating those strategies.

An equally pressing issue identified by survey respondents is an employer branding deficit: The company’s image as an employer is not strong enough to compete for talent in overseas countries, which limits appeal to local talent pools in key markets and exacerbates recruitment hurdles. Equally critical is the governance imbalance: over-centralized decision-making at headquarters stifles regional autonomy, underscoring the need for “glocalized” leadership that balances global oversight with local empowerment to foster engagement and trust. Further complications include cultural integration gaps: inadequate cross-cultural dissemination of corporate values and suboptimal collaboration models in areas like cognitive approaches and language alignment as well as management styles increase operational friction.

Addressing these challenges is not optional but is a strategic imperative for business continuity and global success. Interviewees reinforced the adage “Get the right people onboard, and you’re halfway to victory,” noting that the competitive edge gained through precision hiring—especially in accelerating time to market—far outweighs its costs.

Examining the current international talent practices of Chinese pharmaceutical companies expanding overseas reveals several notable trends beyond their structural characteristics and challenges.

The survey showed that the leadership composition of globally expanding pharmaceutical companies typically follows three predominant patterns: direct local hiring in target markets, strategic expatriation of experienced professionals from Chinese industry peers, and systematic internal promotions.

Companies demonstrate strategic adaptability by capitalizing on regional talent advantages, and the survey illustrated some already developed practices in which the overseas teams primarily focus on formulating R&D strategy and capturing cutting-edge international insights, while their China-based counterparts leverage domestic efficiency and cost competitiveness to drive these R&D operations. This deliberate functional allocation not only optimizes regional talent utilization but also creates a synergistic global-local dynamic that enhances overall organizational effectiveness.

The survey also indicated that China’s pharmaceutical companies are adopting more pragmatic approaches to talent acquisition in pursuit of global competitiveness. Instead of seeking elusive “perfect” candidates, some organizations are strategically building collaborative teams by carefully deconstructing role requirements and reassembling groups of professionals with complementary skill sets. This approach has been shown to foster powerful synergies where collective strengths offset individual limitations, ultimately enhancing team performance and driving sustainable competitive advantage in international markets.

The survey also showed that some companies are collaborating with specialized local executive search partners to strengthen their talent pipelines. These partnerships also yield valuable market intelligence such as regional industry dynamics, compensation benchmarks, and regulatory landscapes, which inform tailored recruitment strategies. Beyond the hiring process, some human resources teams implement structured onboarding and integration programs designed to cultivate trust between new hires and leadership in an effort to improve talent retention rates over time.

Summary

The Blue Book Opportunities and Challenges for International Talent in China’s Innovative Pharma Companies’ Global Expansion illustrates how the international expansion of Chinese pharmaceutical companies has evolved beyond simple geographic and operational extension to embody a fundamental transformation in global preparedness and leadership paradigms and enable organizational metamorphoses. This journey represents nothing less than the maturation of China’s biopharmaceutical sector onto the world stage, as these enterprises navigate the complexities of globalization—not just for securing a foothold abroad, but for sustaining competitive advantage and building enduring worldwide impact, firmly upholding core values while demonstrating a strong adaptability to diverse contexts.

Global expansion of Chinese pharmaceutical companies is entering a transformative phase that moves beyond simply transplanting domestic successes abroad. This new era demands a fundamental evolution in organizational culture, one that achieves genuine global integration while maintaining an unwavering commitment to core values alongside actual contextual adaptability. At its heart, this cultural evolution represents a delicate balancing act: preserving the essence of what makes these organizations unique while developing the flexibility to thrive across varied cultural landscapes. The most successful companies will be those that master this duality to build organizational cultures that are both globally consistent and locally relevant. This cultural agility, combined with technical excellence, will define the next generation of global pharmaceutical leaders.